* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on August 3.
* The Austin Texas-based company is expected to report a
65.7% increase in revenue to $1.111 billion from $670.13 million
a year ago, according to the mean estimate from 15 analysts,
based on Refinitiv data. The company's guidance on May 9 2023,
for the period ended June 30, was for revenue between $1.11
billion and $1.12 billion.
* Refinitiv's mean analyst estimate for agilon health inc
is for
a loss of 3 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for agilon
health inc
is $29, above its last closing price of $18.30.
The company's guidance on May 9 2023 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD1.105 billion and USD10 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.02 0.02 0.04 Beat 83.3
Dec. 31 2023 -0.07 -0.09 -0.14 Missed -62.8
Sep. 30 2022 -0.06 -0.05 -0.07 Missed -40
Jun. 30 2022 -0.02 -0.02 -0.05 Missed -177.8
Mar. 0.00 0.00 0.00 Met -100
31 2022
Dec. 31 2021 -0.14 -0.11 -0.14 Missed -27.3
Sep. 30 2021 -0.10 -0.10 -0.09 Beat 6.9
Jun. 30 2021 -0.06 -0.05 -0.79 Missed -1,336
.4
This summary was machine generated August 2 at 02:05 GMT. All
figures in US dollars unless otherwise stated